F D C

F D C EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of F D C (FDC.NS) as of Oct 27, 2026 is 22.48. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 39.46 — a change of -43.03% (lower).

EV/FCF

22.48

YoY

-43.03%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of F D C is 2025 22.48 . EV/FCF (Enterprise Value to Free Cash Flow) of F D C was 2024 39.46 . It decreases by -43.03% lower compared to the previous year.

The F D C EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
44.89 INR
Jan 1, 2019
72.65 INR
Jan 1, 2020
22.59 INR
Jan 1, 2021
34.19 INR
Jan 1, 2022
170.95 INR
Jan 1, 2023
120.25 INR
Jan 1, 2024
39.46 INR
Jan 1, 2025
22.48 INR
The F D C EV/FCF history
YEAREV/FCFYoY
22.48-43.03%
39.46-67.18%
120.25-29.66%
170.95+400.06%
34.19+51.32%
22.59-68.90%
72.65+61.85%
44.89+14.63%
39.16-201.19%
-38.70-153.32%
72.58-101.90%
-3,810.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

EV/FCF (Enterprise Value to Free Cash Flow) of F D C is 22.48 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of F D C changed from 39.46 to 22.48, representing a -43.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) F D C since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s F D C with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — F D C

All Key Metrics — F D C